Crossref
Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · e11-e12
DOI: 10.1016/j.cgh.2026.07.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology, 24(10), e11-e12. https://doi.org/10.1016/j.cgh.2026.07.030
Vancouver
Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026;24(10):e11-e12. doi:10.1016/j.cgh.2026.07.030
BibTeX
@article{euvimed2026,
title = {Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {10},
pages = {e11--e12},
doi = {10.1016/j.cgh.2026.07.030}
}
EUVIMED